Theorem Clinical Research

Shire

PharmaTimes recognizes top U.S. clinical researchers

Tuesday, November 19, 2013 01:00 PM

Winners of the U.S. Clinical Researcher of the Year competition were announced following an intense finals day hosted by partner SAS at its global headquarters in Cary, N.C.

More... »


U.S. Clinical Researchers of the Year announced

Tuesday, November 12, 2013 08:00 AM

The 2013 U.S. Clinical Researchers of the Year winners have been revealed at the Umstead Hotel in North Carolina, U.S.

More... »


Shire to acquire ViroPharma for $4.2 billion

Monday, November 11, 2013 02:55 PM

Shire and ViroPharma have entered a merger agreement in which Shire will acquire all the outstanding shares of ViroPharma in a cash deal valued at a total of $4.2 billion.

More... »

Shire updates reorganization program, Basingstoke site consolidated

Friday, November 8, 2013 12:10 PM

Shire Pharmaceuticals has updated its “One Shire” program and has initiated an employee consultation process at its site in Basingstoke.

More... »

Shire, Santaris extend collaboration to discover and develop LNA-drugs

Friday, August 23, 2013 12:29 PM

Santaris Pharma, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has announced that its long-term partner, Shire, has extended the existing partnership in the rare genetic disease space.  

More... »

Heptares grants Shire worldwide NDC license

Wednesday, July 3, 2013 10:00 AM

Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares Therapeutics, currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

More... »

Biogen Idec, WPI to develop programs for BETC

Friday, May 31, 2013 10:50 AM

Global biotechnology company Biogen Idec has signed a collaboration agreement with Worcester Polytechnic Institute (WPI) to develop and deliver programs at the university’s Biomanufacturing Education and Training Center (BETC) of Worcester, Mass.

More... »

NeuroPhage raises $6.4M in additional financing

Monday, May 6, 2013 02:40 PM

NeuroPhage Pharmaceuticals, a company developing breakthrough therapies for neurodegenerative diseases, has raised $6.4 million in a private equity financing round. Mérieux Développement led the financing with participation from all current Neurophage investors, including Shire.  

More... »

Shire to acquire SARcode Bioscience, expand presence in ophthalmology

Monday, March 25, 2013 09:42 AM

Global specialty biopharmaceutical company Shire has agreed to acquire SARcode Bioscience, a Brisbane, Calif.-based privately held biopharmaceutical company. The acquisition continues to build Shire's presence in the ophthalmology therapeutic category and brings a new phase III compound—Lifitegrast—currently under development for the signs and symptoms of dry eye disease, into Shire's portfolio.

More... »

Shire acquires Premacure

Wednesday, March 13, 2013 09:41 AM

Global specialty biopharmaceutical company Shire has acquired Premacure, a Swedish privately held biotechnology company developing a protein replacement therapy, currently in phase II development for the prevention of retinopathy of prematurity (ROP).

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs